North America Cannula Market Report

North America Cannula Market Size

The North American Cannula Market size was valued at USD 191.14 billion in 2024 and is estimated to be growing at a CAGR of 5.51%, to reach USD 308.81 billion by 2033 from USD 201.07 billion in 2025.

A cannula refers to a thin, flexible tube used in medical settings for the insertion into body cavities, ducts, or vessels, primarily for the administration of fluids, medication, or for the withdrawal of bodily fluids. In the context of the North America Cannula Market, these devices are extensively used across hospitals, ambulatory surgical centers, and home healthcare environments. The market encompasses a wide range of cannula types such as nasal cannulas, intravenous (IV) cannulas, arterial cannulas, and specialized variants used in surgeries like cardiopulmonary bypass procedures. As per the Centers for Disease Control and Prevention (CDC), over 133 million Americans live with at least one chronic condition, significantly driving the need for infusion therapies and oxygen delivery systems that utilize cannulas. The region also benefits from strong reimbursement policies and regulatory support from bodies like the Food and Drug Administration (FDA), which encourages innovation and rapid integration of novel cannula designs into clinical practice.

MARKET DRIVERS

Rising Prevalence of Chronic Respiratory Diseases

One of the key drivers propelling the North America Cannula Market is the escalating incidence of chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea. According to the American Lung Association, approximately 16 million Americans have been diagnosed with COPD, though the actual number may be higher due to underdiagnosis. Patients suffering from these ailments often require long-term oxygen therapy, where nasal cannulas serve as the primary delivery method. Oxygen therapy usage has surged, particularly post-COVID-19, as many survivors experience lingering pulmonary complications. Moreover, the aging population in the United States and Canada contributes significantly to this trend. Older adults are more susceptible to respiratory illnesses, necessitating frequent hospitalization and home-based oxygen therapy. The U.S. Census Bureau projects that by 2030, all baby boomers will be aged 65 or older, creating a larger patient pool reliant on oxygen support systems. This growing demographic is expected to increase the utilization of nasal and transtracheal cannulas, especially in outpatient and home care settings. Companies manufacturing cannulas are responding by developing lightweight, high-flow, and comfort-oriented models tailored for extended use.

Growth in Minimally Invasive Surgical Procedures

The expansion of minimally invasive surgical (MIS) procedures is another critical factor fueling the North America Cannula Market. Cannulas play an essential role in MIS by enabling access to internal organs without the need for large incisions, thereby reducing recovery time and infection risks. The preference for laparoscopic and endoscopic techniques across specialties such as cardiology, urology, and orthopedics has led to increased usage of surgical cannulas. Technological advancements have also played a pivotal role in this growth. Innovations such as anti-kink cannulas, hydrophilic-coated models, and smart cannulas integrated with sensors are gaining traction in operating rooms. As per data published by the Society of Laparoendoscopic Surgeons, around 70% of abdominal surgeries in the U.S. now employ laparoscopic methods, directly contributing to higher cannula consumption. Furthermore, the American College of Surgeons notes that MIS reduces hospital stays by up to 40%, making it cost-effective and preferred by both patients and providers.

MARKET RESTRAINTS

Stringent Regulatory Requirements for Medical Device Approval

One of the primary restraints affecting the North America Cannula Market is the rigorous regulatory framework governing the approval and commercialization of medical devices. The U.S. Food and Drug Administration (FDA) enforces stringent guidelines under the Federal Food, Drug, and Cosmetic Act, requiring manufacturers to undergo extensive preclinical testing, clinical trials, and quality system audits before launching new cannula products. These prolonged approval timelines not only delay product launches but also increase research and development costs for manufacturers. A report by AdvaMed indicated that small and medium-sized enterprises face an average cost of $3 million to bring a new medical device to market, excluding post-market surveillance expenses. Such financial burdens discourage innovation and limit the entry of new players into the market. Additionally, evolving regulations related to biocompatibility, sterilization, and labeling further complicate compliance efforts. For instance, the FDA’s updated guidance on medical device cybersecurity in 2023 introduced additional requirements for electronic components in smart cannulas, adding complexity for tech-integrated device developers.

Shortage of Skilled Healthcare Professionals and Improper Cannula Usage

Improper handling and misuse of cannulas due to a shortage of trained healthcare personnel represent a significant restraint on the North America Cannula Market. Although the demand for cannulation procedures is increasing, the availability of adequately trained clinicians who can perform these tasks safely remains a concern. According to the American Nurses Association, the U.S. could face a nursing shortage of over 1 million by 2030, exacerbating existing staffing gaps in hospitals and outpatient facilities. These complications not only lead to patient discomfort but also result in increased healthcare costs and potential litigation. Moreover, improper cannula use contributes to unnecessary device replacements, leading to supply waste and inflated procurement expenses for healthcare institutions. The Joint Commission has cited inadequate training as a contributing factor in several adverse events linked to vascular access devices.

MARKET OPPORTUNITIES

Expansion of Home Healthcare Infrastructure

A significant opportunity for growth in the North America Cannula Market lies in the expanding home healthcare sector. There has been a notable shift from hospital-centric care to decentralized, home-based care models with increasing patient preference for home-based treatments and the rising burden of chronic diseases. This expansion creates a favorable environment for the increased use of nasal cannulas, peripheral IV lines, and other cannulation devices outside traditional clinical settings. The convenience of home oxygen therapy (HOT) is a major driver of this trend. Data from the American Thoracic Society indicates that over 1.5 million Americans currently receive HOT, primarily using nasal cannulas for long-term oxygen support. The Centers for Medicare & Medicaid Services (CMS) has also expanded reimbursement coverage for home-based oxygen delivery systems, encouraging broader adoption among patients with chronic respiratory conditions. Additionally, advancements in portable oxygen concentrators and lightweight cannula designs have improved patient mobility and comfort, enhancing adherence to prescribed therapies. Manufacturers are capitalizing on this shift by introducing user-friendly, disposable, and antimicrobial-treated cannulas designed specifically for home use.

Integration of Smart Technologies in Cannula Design

The incorporation of smart technologies into cannula design presents a transformative opportunity for the North America Cannula Market. Traditional cannulas are passive devices, but recent innovations have introduced sensor-equipped models capable of real-time monitoring of physiological parameters such as blood flow, temperature, and oxygen saturation. Companies such as Becton Dickinson, Teleflex Incorporated, and Smiths Medical are investing heavily in R&D to develop intelligent cannulation solutions. For example, BD's Alaris™ infusion platform integrates smart pumps with compatible IV cannulas to reduce medication errors and enhance patient safety. Similarly, emerging startups are working on wireless cannulas embedded with micro-sensors that transmit real-time data to electronic health records (EHRs). Furthermore, the increasing use of artificial intelligence (AI) and machine learning in predictive analytics allows early detection of complications such as occlusion or infiltration. These advancements not only improve patient monitoring but also reduce hospital readmissions and associated costs.

MARKET CHALLENGES

High Risk of Catheter-Related Bloodstream Infections (CRBSIs)

A significant challenge confronting the North America Cannula Market is the persistent risk of catheter-related bloodstream infections (CRBSIs), which pose serious threats to patient safety and healthcare economics. Intravenous (IV) cannulas, especially those used for central venous access, are prone to microbial colonization, leading to life-threatening infections. The Agency for Healthcare Research and Quality (AHRQ) reports that up to 68% of CRBSIs are preventable with strict adherence to evidence-based protocols; however, inconsistent implementation across healthcare settings continues to undermine progress. Furthermore, the emergence of multidrug-resistant organisms complicates treatment strategies, which is limiting the effectiveness of conventional antibiotics. In response, manufacturers are developing innovative solutions such as silver-coated cannulas and antimicrobial lock solutions to reduce infection rates.

Supply Chain Disruptions and Raw Material Constraints

Cannulas are typically manufactured using medical-grade polymers such as polyurethane, silicone, and PVC, all of which are subject to fluctuating global supply dynamics. The reliance on a limited number of suppliers for specialized resins and additives has exacerbated the situation. For instance, the U.S. imports over 60% of its medical-grade polymer supply, primarily from Asia and Europe.

SEGMENTAL ANALYSIS

By Application Insights

The oxygen therapy segment was the largest by occupying 35.4% of the North America Cannula Market share in 2024 owing to the rising prevalence of chronic respiratory diseases such as COPD, asthma, and pulmonary fibrosis. According to the American Lung Association, more than 16 million Americans suffer from diagnosed COPD, with many requiring long-term oxygen support. The widespread use of nasal cannulas for delivering low to moderate concentrations of oxygen has made this segment a cornerstone of home healthcare and hospital-based treatment protocols.

The rising geriatric population is prompting the growth of the segment. As per the U.S. Census Bureau, the number of Americans aged 65 and older is projected to reach 95 million by 2060, significantly increasing the pool of individuals susceptible to respiratory ailments. Additionally, post-COVID-19 recovery cases have further intensified the demand for oxygen delivery systems.

The cardiovascular segment is projected to expand at a CAGR of 8.5% in the coming years due to the rising incidence of cardiovascular diseases (CVDs), which remain the leading cause of mortality in the region. According to the Centers for Disease Control and Prevention (CDC), heart disease accounts for about 655,000 deaths annually in the United States alone. Technological advancements are further accelerating adoption rates. Innovations such as arterial cannulas with anti-thrombogenic coatings and improved flow dynamics are enhancing procedural safety and reducing complications. The Society of Thoracic Surgeons notes that over 500,000 open-heart surgeries are performed each year in the U.S., directly driving demand for high-performance cannulation devices.

By Product Insights

The nasal cannulas segment held 30.1% of the North America Cannula Market share in 2024 with the usage in both clinical and homecare settings makes them indispensable in oxygen delivery systems. The primary driver behind this dominance is the escalating prevalence of chronic respiratory disorders among the elderly. According to the American Lung Association, over 16 million Americans suffer from chronic obstructive pulmonary disease (COPD), many of whom rely on nasal cannulas for long-term oxygen therapy. Additionally, the rise in post-hospitalization home healthcare services has significantly boosted demand. The Centers for Medicare & Medicaid Services (CMS) also expanded coverage for home oxygen equipment, making it more accessible to patients. Technological advancements, including lightweight, non-irritating designs and disposable variants, have further enhanced patient compliance.

The cardiac cannula segment is likely to grow with a CAGR of 9.3% in the next coming years. This robust growth trajectory is fueled by the rising burden of cardiovascular diseases, which remains the leading cause of death in the region. Innovation in surgical techniques is another key catalyst. The adoption of minimally invasive cardiac surgeries and hybrid procedures has led to higher demand for precision-engineered cannulas designed for reduced trauma and improved hemodynamic stability. Furthermore, the integration of biocompatible materials and antithrombotic coatings in next-generation cardiac cannulas enhances safety and longevity, encouraging broader clinical acceptance.

By Material Insights

The plastic segment was the largest by occupying 55.4% of the North America Cannula Market share in 2024. Polyvinyl chloride (PVC), polyurethane, and polyethylene are widely used due to their flexibility, ease of manufacturing, and ability to be sterilized using various methods. According to the Plastics Industry Association, over 60% of disposable medical devices in the U.S. are manufactured using medical-grade plastics. The preference for single-use, disposable plastic cannulas is further reinforced by infection control concerns. The Centers for Disease Control and Prevention (CDC) highlights that healthcare-associated infections (HAIs) affect approximately 1 in 31 hospital patients at any given time, prompting hospitals to favor disposable options. Moreover, regulatory agencies such as the FDA continue to endorse the use of polymer-based medical devices due to their proven safety profile.

The silicone segment is deemed to grow with a CAGR of 7.5% over the forecast period. One of the major applications propelling silicone cannula adoption is in chronic wound management and tracheostomy care, where prolonged use without irritation is essential. Data from the Wound Healing Society indicates that over six million Americans suffer from chronic wounds annually, necessitating durable and skin-friendly cannulation solutions. Additionally, silicone’s inert nature reduces the risk of allergic reactions, making it preferable for neonatal and pediatric care. The U.S. Food and Drug Administration (FDA) also recognizes silicone as a Class II medical device material, ensuring its widespread regulatory acceptance.

By End User Insights

The hospitals segment held a prominent share of the North America Cannula Market in 2024. The surge in emergency admissions and surgical volumes further reinforces this segment's dominance. The Healthcare Cost and Utilization Project (HCUP) reports that over 35 million inpatient stays occurred in U.S. hospitals in 2022, with a significant portion involving IV or nasal cannula use. Moreover, hospitals are early adopters of advanced cannulation technologies, including antimicrobial-coated and smart infusion-ready models. The Centers for Disease Control and Prevention (CDC) also emphasizes the importance of infection prevention in acute care settings, driving demand for high-quality disposable cannulas.

The Ambulatory Surgical Centers (ASCs) segment is likely to grow with a CAGR of 8.3% in the next coming years. This rapid expansion is primarily driven by the shift toward outpatient procedures, which offer lower costs, reduced hospital-acquired infection risks, and greater patient convenience. The increasing adoption of minimally invasive surgical techniques in ASCs is another key factor. Procedures such as laparoscopic surgeries, arthroscopies, and endoscopies often require the use of specialized cannulas for access and fluid management. Additionally, favorable reimbursement policies from CMS and private insurers have encouraged the migration of procedures from hospitals to outpatient centers.

REGIONAL ANALYSIS

United States Cannula Market Insights

The United States was the top performer of the North America Cannula Market by occupying 80.1% of the share in 2024 with a highly developed healthcare infrastructure, extensive research and development activities, and a high prevalence of chronic diseases requiring cannulation therapies. Moreover, the U.S. benefits from strong regulatory support and favorable reimbursement policies. The Centers for Medicare & Medicaid Services (CMS) provides extensive coverage for home oxygen therapy and hospital-based infusion treatments, enabling widespread access to cannulation devices. Additionally, the country leads in technological innovation, with companies like Becton Dickinson, Medtronic, and Teleflex Incorporated continuously introducing advanced cannula designs equipped with antimicrobial coatings and smart monitoring features.

Canada Cannula Market Insights

Canada cannula market held 15.4% of the share in 2024. The country’s well-established public healthcare system, combined with rising investments in medical technology, supports a steady increase in cannula adoption. The Canadian Institute for Health Information (CIHI) notes that over 3.2 million surgical procedures were performed in Canadian hospitals in 2022, many of which involved the use of surgical and vascular cannulas. Additionally, the expansion of home healthcare services, supported by provincial health programs such as Ontario’s Community Support Services Program, has increased access to nasal oxygen therapy. The Canadian government has also been proactive in adopting digital health initiatives, facilitating the integration of smart cannulation devices into clinical practice.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Companies playing a dominant role in the North American Cannula Market profiled in this report are Medtronic plc (U.S.), Edward Lifesciences Corp. (U.S.), Terumo Corporation (Japan), Sorin Group (Italy), and Maquet Holding B.V. & Co. KG (Germany) among others.

The competition in the North America Cannula Market is intense, characterized by the presence of well-established global players and a growing number of regional manufacturers. The market landscape is shaped by continuous product innovation, strategic collaborations, and aggressive expansion initiatives aimed at capturing larger shares. Major companies focus on enhancing their product portfolios with advanced features such as antimicrobial properties, improved biocompatibility, and ergonomic designs to differentiate themselves from competitors. Additionally, there is a strong emphasis on strengthening distribution networks and securing long-term contracts with healthcare providers to ensure consistent demand. While large multinational corporations dominate due to their extensive resources and brand recognition, mid-sized firms are increasingly leveraging niche technologies and specialized applications to carve out their own space. Regulatory compliance, pricing pressures, and the need for cost-effective yet high-quality products further influence competitive dynamics, which is making it essential for players to maintain agility and responsiveness to market trends.

Top Players in the North America Cannula Market

Becton, Dickinson and Company (BD)

BD is a leading global medical technology company with a strong presence in the cannula market. The company offers a broad portfolio of vascular access solutions, including IV and nasal cannulas designed for enhanced patient safety and comfort. BD’s commitment to innovation has led to the development of advanced products featuring antimicrobial coatings and integrated safety mechanisms. Their extensive distribution network and continuous investment in research ensure a dominant position in both hospital and homecare settings across North America.

Teleflex Incorporated

Teleflex is a major player known for its high-quality vascular and surgical cannulation products. The company focuses on delivering technologically superior solutions that improve clinical outcomes. Teleflex emphasizes product differentiation through design enhancements and performance-driven engineering. Its strong brand reputation and strategic acquisitions have allowed it to maintain a competitive edge. Teleflex continues to expand its footprint by collaborating with healthcare providers to meet evolving clinical needs in the North American market.

Smiths Medical (A part of ICU Medical, Inc.)

Smiths Medical is recognized for its reliable and innovative cannulation devices used in critical care, surgery, and respiratory therapy. The company prioritizes patient and clinician safety through ergonomic designs and user-friendly features. Smiths Medical maintains a strong market presence due to its focus on quality assurance and regulatory compliance. The company plays a crucial role in shaping the dynamics of the North America Cannula Market with a diverse product lineup tailored to various medical applications.

Top Strategies Used by Key Market Participants

One major strategy employed by key players is continuous product innovation and technological advancement. Companies are investing heavily in R&D to develop next-generation cannulas with improved safety features, such as antimicrobial coatings, anti-kink designs, and smart integration for real-time monitoring. These innovations help reduce complications and enhance patient outcomes, giving manufacturers a competitive advantage.

Another key approach is strategic partnerships and collaborations. Leading firms are aligning with hospitals, research institutions, and digital health companies to integrate their cannulation solutions into broader clinical workflows. These alliances support data-driven improvements and facilitate faster adoption of new products within healthcare systems across North America.

The market expansion through mergers and acquisitions is widely adopted. By acquiring smaller firms or complementary businesses, major players enhance their product portfolios, geographic reach, and manufacturing capabilities. This allows them to consolidate their market position and respond more effectively to evolving customer demands.

RECENT MARKET DEVELOPMENTS

• In January 2024, BD launched a new line of antimicrobial-coated peripheral IV cannulas designed to reduce catheter-related bloodstream infections by reinforcing its dominance in infection control solutions.
• In March 2024, Teleflex Incorporated introduced an upgraded version of its pressure-monitoring vascular cannula system, offering enhanced accuracy and ease of use for critical care applications.
• In June 2024, Smiths Medical expanded its U.S. manufacturing facility to increase production capacity for nasal and surgical cannulas, which is aiming to meet rising domestic demand and reduce supply chain dependencies.
• In September 2024, ICU Medical acquired a small med-tech startup specializing in smart infusion accessories, which is integrating these technologies into its existing cannulation product line to enhance digital compatibility.
• In November 2024, B. Braun partnered with a leading telehealth provider to incorporate its cannulation devices into remote patient monitoring programs, which supports the shift toward home-based care models.

MARKET SEGMENTATION

This research report on the North America Cannula Market has been segmented and sub-segmented into the following categories:

By Application

• Oxygen Therapy
• General Surgery
• Cardiovascular Surgery
• Plastic Surgery
• Orthopedic Surgery
• Other Applications

By Product

• Vascular Cannulas
• Cardiac Cannulas
• Arthroscopy Cannulas
• Nasal Cannulas
• Dermatology Cannulas
• Other Products

By Material

• Metal
• Silicone
• Plastic

By End Users

• Hospitals
• Ambulatory Surgical Centres
• Other End Users

By Country

• The United States
• Canada
• Rest of North America